GW Pharmaceuticals created the first FDA-approved CBD-based drug, Epidiolex. Now, the company is turning its attention from seizure disorders to autism. The cannabis pharmaceutical company is currently conducting a new clinical trial at Montefiore Medical Center in New York which will examine the effects of CBDV, or cannabidivarin, on autism spectrum
On Wednesday, FDA commissioner Scott Gottlieb announced his resignation, citing the toll the job takes on family life. The resignation could be a setback for the CBD industry, which is eagerly awaiting clarification from the FDA on how CBD will be regulated in the future.
In last week’s roundup, we noted that the World Health Organization’s Expert Committee on Drug Dependence had not yet presented their recommendations for the international scheduling of cannabis. The committee had been scheduled to release the report in December 2018. This week, the wait is finally over. The committee shared